BGM Group
BGM Group's revenue rose 51.1% to $38 million in fiscal 2025. Its operating margin was −33.2%, down from −2.2% a year earlier. Free cash flow was −$4 million, against $0 million a year earlier. The diluted share count rose 1467.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What BGM Group does
BGM Group is a holding company in the Cayman Islands whose business is in China. It does not own its main Chinese operating company, Gansu QLS, outright: it controls it through a set of contracts, a setup known as a variable interest entity (VIE), because Chinese rules limit foreign ownership in some industries. Buyers of its shares hold an interest in the Cayman company, not in the Chinese businesses.
Its older business makes medicines and related goods at plants in Gansu and Sichuan provinces: licorice-based cough medicines and extracts, the antibiotic oxytetracycline for farm animals and people, heparin (a raw material for blood-thinning drugs), an herbal skin paste, sausage casings and fertilizers. It sells them in more than 20 Chinese provinces to distributors, dealers and drug companies, and in its 2025 fiscal year two customers made up 16% and 11% of these sales. It says it competes with other Chinese makers of similar products, mainly on price and its location in western China.
In 2025 it bought an insurance agency business, which earns commissions from insurers on policies sold, and it now also offers artificial intelligence tools to insurers and brokers. For the year ended September 30, 2025, its net revenue was $37.92 million, of which the new insurance business brought in $10.96 million.
Its biggest risks, as it describes them
- China could decide that its contracts with the VIE break foreign-ownership rules, costing it control of the business.
- The Chinese government has wide power over its operations and over offerings made by China-based companies abroad.
- The VIE's owners may have conflicts of interest with the company and its shareholders.
- Changes in China's insurance rules could restrict its new insurance agency business or bring more competition.
- Product liability claims from its medicines, and its reliance on a few key managers.
Income statement
From fiscal 2018 to 2022, earnings per share fell 35.2% a year and net income 32.2% a year, as new shares raised the share count by 20% and diluted each share's earnings. BGM Group then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 10 | 14 | 8 | — | 10 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 41.4x | 17.2x | −713.9x | −132.3x | −356.1x |
| Current ratio | 2.2x | 3.3x | 5.2x | 3.4x | 1.2x |
| Quick ratio | 1.5x | 2.3x | 4.4x | 2.8x | 0.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −28.1% | −44.8% | 40.7% |
| Altman Z'' | 10.34 | 7.99 | 9.65 |
| Accruals ratio | −14.0% | −3.8% | −7.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | — |
Compare
Put BGM Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| BGM Group | FY25 | 51.1% | −33.2% | −10.4% | — | — | — | |
| Verrica Pharmaceuticals | FY25 | 370.2% | −34.2% | −49.5% | — | — | 5 | Compare |
| Xilio Therapeutics | FY25 | 589.9% | −95.9% | −12.6% | — | — | — | Compare |
| Nanobiotix | FY25 | — | −33.2% | −104.2% | — | — | — | Compare |
| Aquestive Therapeutics | FY25 | −22.6% | −159.5% | −119.0% | — | — | 2 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 50 | 46 | 50 | 57 | 65 | 46 | 25 | 38 |
| Revenue growth | — | −8.5% | 8.5% | 14.1% | 13.6% | −28.4% | −46.0% | 51.1% |
| Gross profit | 8 | 10 | 8 | 6 | 6 | 2 | 4 | 6 |
| Research and development | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Operating income | 6 | 6 | 5 | 2 | 2 | −3 | −1 | −13 |
| Net income | 5 | 6 | 5 | 3 | 1 | −8 | −1 | −20 |
| Diluted EPS (US$) | 0.85 | 0.90 | 0.85 | 0.45 | 0.15 | −1.08 | −0.20 | −0.18 |
| Diluted shares (millions) | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 113 |
| Cash flow | ||||||||
| Cash from operations | 4 | −1 | 5 | 0 | 13 | 0 | 0 | −2 |
| Capital expenditure | 1 | 1 | 0 | 2 | 2 | 0 | 0 | 2 |
| Free cash flow | 3 | −1 | 5 | −1 | 11 | 0 | 0 | −4 |
| Dividends paid | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | — | 0 | — | — | 10 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 6 | 5 | 12 | 10 | 14 | 8 | — | 10 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 35 | 48 | 75 | 64 | 51 | 53 | 434 |
| Total liabilities | — | 13 | 19 | 19 | 10 | 7 | 9 | 42 |
| Shareholders' equity | 18 | 20 | 26 | 55 | 53 | 43 | 43 | 391 |
| Margins and ratios | ||||||||
| Gross margin | 16.1% | 21.0% | 15.1% | 9.9% | 9.6% | 3.8% | 16.4% | 16.6% |
| Operating margin | 11.9% | 13.4% | 9.6% | 4.2% | 3.2% | −5.6% | −2.2% | −33.2% |
| Net margin | 10.3% | 12.8% | 10.1% | 5.5% | 1.7% | −16.7% | −5.8% | −52.6% |
| Free cash flow margin | 6.6% | −2.6% | 9.2% | −2.0% | 16.4% | 0.3% | 1.2% | −10.4% |
| Rule of 40 (growth + FCF margin) | — | −11.1% | 17.8% | 12.1% | 30.0% | −28.1% | −44.8% | 40.7% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | 22.0% | 7.8% | 2.0% | −16.2% | −3.4% | −9.2% |
| Return on assets | — | — | 12.1% | 5.1% | 1.5% | −13.4% | −2.8% | −8.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |